On Monday, Shares of Tenaris SA (ADR)(NYSE:TS), added 2.49% and closed at $31.68 in the last trading session. The last trading range of the stock ranges between $30.55 and $31.71. Tenaris S.A. ( NYSE : TS ) ( BAE : TS ) ( BMV : TS ) ( MILAN : TEN ) (“Tenaris”) recently declared its results for the quarter and nine months ended September 30, 2016 with comparison to its results for the quarter and nine months ended September 30, 2015.
Keryx Biopharmaceuticals (NASDAQ: KERX), dropped -1.56% and closed at $6.29 in the last trading session. The last trading range of the stock ranges between $5.82 and $6.47. The company’s Market capitalization is $757.34 million with the total Outstanding Shares of 105.96 million. Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, recently declared that the U.S. Food and Drug Administration (FDA) has approved its application for a second drug product contract manufacturer. Patheon Manufacturing Services LLC of Greenville, North Carolina, a leading global provider of pharmaceutical manufacturing services, is now an FDA approved drug product manufacturer of Auryxia®. With FDA approval of this manufacturer, the company has rebuilt supply and will promptly make Auryxia available to wholesalers.
“We are happy with recently’s approval, as it expands our manufacturing capabilities and capacity,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals. “Getting a second drug product manufacturer approved was an important step to ensuring long-term supply of Auryxia is consistently available to patients.”
Celgene Corporation (NASDAQ:CELG), gained 1.03% and closed at $120.68 in the last trading session. The last trading range of the stock ranges between $118.17 and $121.65. Company stock’s 52-week range is $93.05 – $127.00 Celgene Corporation (CELG) recently declared findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Washington, D.C. The trial met its primary endpoint of noteworthyimprovement in the proportion of patients achieving an ACR20 response at week 16 with OTEZLA as compared to placebo in patients with active psoriatic arthritis who have not formerly been treated with a biologic therapy.
The ACTIVE trial randomized 219 patients who may have had one prior conventional therapy and were not formerly treated with a biologic to either OTEZLA 30 mg twice daily (n=110) or placebo (n=109). An objective of the study was to determine the clinical effects of OTEZLA contrast with placebo, by examining efficacy outcomes at earlier time points than in previous studies.